The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

pharosibt.com

Founded Year

2016

Stage

Series C | Alive

Total Raised

$35.41M

Last Raised

$15.91M | 1 yr ago

About Pharos iBio

Pharos iBio is a drug discovery and development biotech company specializing in analyzing big data based on IT technology. The company uses artificial intelligence techniques to predict the various properties of a compound, and introduces a low-cost and efficient new drug development system. Pharos iBio is focusing on the development of new drugs with orphan and rare diseases, which can shorten the development period and have a high success rate of NDA approval.

Pharos iBio Headquarter Location

38, Heungan-daero 427beon-gil, Dongan-gu #1407 & 1408

Anyang, 14059,

South Korea

+82-31-345-6170

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Pharos iBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pharos iBio is included in 3 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health

12,808 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

B

Biopharma Tech

838 items

Pharos iBio Patents

Pharos iBio has filed 2 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Acute myeloid leukemia
  • Breast cancer
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/29/2019

Radiation therapy, Medical physics, Cancer treatments, Transcription factors, Acute myeloid leukemia

Application

Application Date

5/29/2019

Grant Date

Title

Related Topics

Radiation therapy, Medical physics, Cancer treatments, Transcription factors, Acute myeloid leukemia

Status

Application

Latest Pharos iBio News

Pharos iBio’s AML drug candidate wins FDA’s orphan drug status

Nov 10, 2021

Pharos iBio’s AML drug candidate wins FDA’s orphan drug status 바로가기 기자명 Shim Hyun-tai 닫기 Pharos iBio said its PHI-501, a next-generation anticancer drug for acute myeloid leukemia (AML), has won orphan drug designation from the U.S. Food and Drug Administration (FDA). Pharos iBio’s PHI-501, a next-generation anticancer drug for acute myeloid leukemia (AML), has won orphan drug status from the U.S. Food and Drug Administration. It was the U.S. regulator’s second orphan drug designation of the Korean company’s product. FDA granted similar status to Pharos iBio’s main pipeline, PHI-101, a next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor for AML, in 2019. PHI-501 is the first targeted anticancer therapeutics against neuroblastoma-RAS (NRAS) mutation using a more effective method for inhibition using synthetic lethality. NRAS is a protein that plays a significant role in cell differentiation, proliferation, and survival in acute myeloid leukemia. However, NRAS mutants continuously send signals for cell growth which also leads to cancer growth. According to Decision Resources Group, a global health industry research firm, AML is a rare disease that shows increased occurrence in the older populations above 65. It is particularly prevalent in the U.S. and Europe. The group expected the global market for AML treatments to reach $2.5 billion by 2025 with a 15 percent annual growth. Pharos iBio holds eight new drug pipelines, including PHI-101, and originally built big data and AI-based platform technology. Through open innovations, the company plans to promote joint research and development and technology transfer with global pharmaceutical companies and overseas organizations. “We will benefit from various incentives, including shortened review period for clinical approval and commercialization, reduced application fee with tax exemption, and a seven-year marketing exclusivity,” said Pharos iBio CDO Han Hye-jung, former principal scientist at Roche Sequencing Solutions. “We will speed up the clinical trials of PHI-501 to enter the global market.” The company has recently built a synthesis and bio laboratory at its headquarters in Anyang, Gyeonggi Province, establishing an infrastructure to discover new drug candidates independently. Pharos iBio received approval for the first phase 1 clinical trial of PHI-101 in Korea and continued to strengthen its ability to develop new drugs for rare and incurable diseases.

  • When was Pharos iBio founded?

    Pharos iBio was founded in 2016.

  • Where is Pharos iBio's headquarters?

    Pharos iBio's headquarters is located at 38, Heungan-daero 427beon-gil, Dongan-gu, Anyang.

  • What is Pharos iBio's latest funding round?

    Pharos iBio's latest funding round is Series C.

  • How much did Pharos iBio raise?

    Pharos iBio raised a total of $35.41M.

  • Who are the investors of Pharos iBio?

    Investors of Pharos iBio include LSK Investment, Intops Investment, Company K Partners, KDB Capital, Solidus Investment and 12 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.